WEST

Help | Logout

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers

Search Results -

Terms	Documents
604/24.ccls. and (cardiac or heart) and (gene adj therapy)	0

Database: US Patents Full-Text Database

Refine Search:

```
604/24.ccls. and (cardiac or heart) and
(gene adj therapy)
```

Search History

DB Name	Query	Hit Count	Set Name
USPT	604/24.ccls. and (cardiac or heart) and (gene adj therapy)	0	L17
USPT	604/93.ccls. and (cardiac or heart) and (gene adj therapy)	0	L16
USPT	604/96.ccls. and (cardiac or heart) and (gene adj therapy)	0	L15
USPT	604/96.ccls. and (connexin adj (40 or 43 or 45)) and (gene adj therapy)	0	L14
USPT	604/93.ccls. and (connexin adj (40 or 43 or 45)) and (gene adj therapy)	0	L13
USPT	604/28.ccls. and (connexin adj (40 or 43 or 45)) and (gene adj therapy)	0	L12
USPT	604/267.ccls. and (connexin adj (40 or 43 or 45)) and (gene adj therapy)	0	L11
USPT	604/266.ccls. and (connexin adj (40 or 43 or 45)) and (gene adj therapy)	0	L10
USPT	435/69.1.ccls. and (connexin adj (40 or 43 or 45)) and (gene adj therapy)	0	L9
USPT	514/44.ccls. and (connexin adj (40 or 43 or 45)) and (gene adj therapy)	0	L8
USPT	435/320.1.ccls. and (connexin adj (40 or 43 or 45)) and (gene adj therapy)	1	L7
USPT	(connexin adj (40 or 43 or 45)) and (gene adj therapy)	2	L6

L2 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2000 ACS
AN 1998:66080 CAPLUS
DN 128:172106
TI **Connexin gene therapy** system for treating cardiac conduction disturbances
IN Stokes, Kenneth B.; Morissette, Josee
PA Medtronic, Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9802150	A1	19980122	WO 1997-US6103	19970404
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2260756	AA	19980122	CA 1997-2260756	19970404
	AU 9724585	A1	19980209	AU 1997-24585	19970404
	EP 957902	A1	19991124	EP 1997-920371	19970404
	R: CH, DE, FR, LI, NL, SE				

PRAI US 1996-682277 19960717

L2 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2000 ACS

AB A method of **gene therapy** is provided which comprises the delivery and expression of a DNA sequence which encodes a protein involved in the regulation of smooth muscle tone in a smooth muscle cell. Also provided is a method of regulating smooth muscle tone in a subject comprising the introduction and expression of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone into a sufficient no. of cells of the subject to regulate muscle tone in the subject. The invention also provides recombinant viral and non-viral vectors comprising DNA encoding a protein involved in the regulation of smooth muscle tone. Further provided by the invention is a smooth muscle cell which expresses a gene encoding a protein involved in the regulation of smooth muscle tone. Specifically disclosed are methods for regulation of bladder smooth muscle tone in e.g. patients with bladder dysfunction. The methodol. of the invention is also applicable to erectile dysfunction.

AN 2000:144766 CAPLUS
DN 132:189688

TI **Gene therapy** for regulating smooth muscle cell tone

IN Christ, George J.; Melman, Arnold
PA Albert Einstein College of Medicine of Yeshiva University, USA

SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000010604	A1	20000302	WO 1999-US18912	19990818

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-135849 19980818

L2 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2000 ACS

AB Cancer preventive retinoids and carotenoids are antiproliferative and up-regulate connexin43 expression and gap junctional communication (GJC). To det. if effects on GJC are central to actions of these compds. we have created HeLa cell clones contg. a tet-inducible Cx43 gene. Clones respond rapidly to induction by doxycycline with Cx43 synthesis and incorporation into junctional plaques. In dense cultures, induction results in decreased proliferation. Clonal heterogeneity among HeLa cells with regard to Cx43 expression and neoplastic phenotype was also discovered. These results support the hypothesis of growth control via GJC.

AN 1998:714455 CAPLUS

DN 130:108402

TI **Connexins** and carcinogenesis: upregulated expression of **connexin** 43 by cancer preventive agents or by gene transfer decreases proliferation and expression of neoplasia

AU King, Timothy J.; Fukushima, Laurie H.; Bertram, John S.

CS Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, 96813, USA

SO Gap Junctions, Proc. Int. Gap Junction Conf., 8th (1998), Meeting Date 1997, 357-361. Editor(s): Werner, Rudolf. Publisher: IOS Press, Amsterdam, Neth.
CODEN: 66XYAX

DT Conference

LA English

(FILE 'HOME' ENTERED AT 11:58:06 ON 03 MAY 2000)

FILE 'MEDLINE, CAPLUS' ENTERED AT 11:58:14 ON 03 MAY 2000

L1 44 S (CONNEXIN) AND (GENE THERAPY)

L2 30 DUPLICATE REMOVE L1 (14 DUPLICATES REMOVED)

L2 ANSWER 28 OF 30 MEDLINE DUPLICATE 13

AB The expression of connexin43, the primary gap-junction constituent of glial cells, was evaluated at the messenger RNA and protein levels in different grades of astrocytoma to investigate the relevance of gap junctions in herpes simplex virus-thymidine kinase (HSV-tk)-mediated **gene therapy** of brain tumors. Transduction of the retroviral-mediated HSV-tk gene into tumor cells with subsequent administration of ganciclovir has recently been used as an experimental therapeutic strategy for treatment of brain tumors. One aspect of this approach is the bystander effect, which augments the efficacy of this therapeutic approach. Glioblastoma cells with minimum levels of connexin43 protein were transfected with a connexin43 complementary DNA. These cells manifested a marked increase in the in vitro bystander effect, supporting the contention that the in vitro bystander effect is a consequence of metabolic cooperation between cells mediated by gap junctions. To assess relative levels of gap-junction protein expression in the relevant tumor type, we examined primary astrocytomas, primary astrocytoma cell cultures, and glioblastoma cell lines. Although most astrocytoma tumor samples expressed connexin43, they differed in the level of expression, with the greatest variation exhibited in high-grade astrocytomas. Primary glioblastoma cell cultures and established glioblastoma cell lines also displayed some variability in connexin43 levels. In aggregate, our results anticipate that glioblastomas will have a varied bystander effect during HSV-tk **gene therapy** depending on the level of connexin43 expression.

AN 96198910 MEDLINE

DN 96198910

TI Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor **gene therapy**.

AU Shinoura N; Chen L; Wani M A; Kim Y G; Larson J J; Warnick R E; Simon M; Menon A G; Bi W L; Stambrook P J

CS Department of Cell Biology, University of Cincinnati, College of Medicine, Ohio, USA.

NC P20-NS31145 (NINDS)

SO JOURNAL OF NEUROSURGERY, (1996 May) 84 (5) 839-45; discussion 846. Journal code: JD3. ISSN: 0022-3085.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 199608